What this story covers

Thermo Fisher Scientific's 2023 10-K reveals revenues down 5 percent to 42 point 9 billion dollars, driven by reduced COVID-19 sales, with organic growth -5 percent. Segments varied: Life Sciences -26 percent, Analytical Instruments +10 percent. Adjusted EPS 21 dollars 55 cents, down 7 percent. Strong free cash flow 7 billion dollars supports acquisitions like Binding Site and proposed Olink. Restructuring saves 0 point 5 billion dollars annually. Liquidity robust with 8 point 1 billion dollars cash.

Story snapshot